Published: 2019-07-24

Role of lipid profile in assessment of severity of cirrhosis

Mahendrapal Singh, Mohd. Imran Khan, A. C. Gupta, Richa Giri, Ashfak Alam


Background: Cirrhosis is defined anatomically as a diffuse process with fibrosis and nodule formation. It is the result of the fibrogenesis that occurs with chronic liver injury. For reduced liver biosynthesis capacity, low level of serum cholesterol, low density lipoprotein (LDL) and high density lipoprotein (HDL) is usually observed in the chronic liver disease. Due to the high prevalence of chronic liver disease in our country we have conducted this study to determine role of lipid profile in a patient with cirrhosis and to assess its relationship to the severity of cirrhosis.

Methods: In this cross-sectional study, patients classified in 3 groups as per CTP classification for severity of cirrhosis. Serum lipid profile was observed in these patients. The primary aim was to assess changes in various parameters of lipid profile and its relationship with severity of liver cirrhosis.

Results: About 74 cirrhotic patients were enrolled, 20 in class A, 25 in class B and 29 in class C. serum lipid profile was observed in these patients. Serum cholesterol and HDL cholesterol were decreased with increasing severity of cirrhosis. Serum triglyceride level increases with progression of cirrhosis and very low density lipoprotein (VLDL) level has no correlation with severity of cirrhosis.

Conclusions: Serum cholesterol and HDL level decreases with progression of cirrhosis. In future serum lipid profile can be used in classification criteria for assessing severity of liver cirrhosis.


Chronic liver disease, CTP classification, Lipid profile, Severity of liver cirrhosis

Full Text:



Seidel D. Lipoproteins in liver disease. Clin Chem Clin Biochem. 1987;25:541-51.

Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Inter Med. 1997;157(7):792-6.

Makarov VK, Khomeriki SG. Serum lipids as biochemical manifestations of hepatic alcoholic, viral, and mixed viral-and-alcoholic lesion. Clin Lab Diagn. 2007(5):17-9.

Mc Intyre N. Plasma lipids and lipoproteins in liver disease. Gut. 1978;19:526-30.

Ooi K, Shiraki K, Sakurai Y, Morishita Y, Nobori T. Clinical significance of abnormal lipoprotein patterns in liver diseases. Inter J Molecule Med. 2005;15(4):655-60.

SelimoĞlu MA, AydoĞdu S, YaĞci RV. Lipid parameters in childhood cirrhosis and chronic liver disease. Ped Inter. 2002;44(4):400-3.

Halsted CH. Nutrition and alcoholic liver disease. Seminars in liver disease Copyright©, 2004. Thieme Medical Publishers, Inc; 2004;24(03):289-304.

Shah SS, Desai HG. Apolipoprotein deficiency and chronic liver disease. J Assoc Physicians India. 2001;49:274-8.

Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930):1749-61.

Pugh R, Murray‐Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Brit J Surg. 1973;60(8):646-9.

Fernández-Esparrach G, Sánchez-Fueyo A, Ginès P, Uriz J, Quintó L, Ventura PJ, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol. 2001;34(1):46-52.

Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatol. 2000;32(5):930-4.

Gluud C, Henriksen JH, Copenhagen Study Group for liver diseases. Prognostic indicators in alcoholic cirrhotic men. Hepatol. 1988;8(2):222-7.

Planas R, Ballesté B, Álvarez MA, Rivera M, Montoliu S, Galeras JA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. a study of 200 patients. J Hepatol. 2004;40(5):823-30.

Gips CH, Reisman Y, Maas KW, Purmer IM, Huizenga JR, Verbaan BW. Major clinical events, signs and severity assessment scores related to actual survival in patients who died from primary biliary cirrhosis. a long-term historical cohort study. Hepato-Gastroenterol. 1999;46(25):108-15.

Shetty K, Rybicki L, Carey WD. The Child‐Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. Hepatol. 1997;25(5):1049-53.

Zeitoun G, Escolano S, Hadengue A, Azar N, El Younsi M, Mallet A, et al. Outcome of Budd‐Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatol. 1999;30(1):84-9.

Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatol. 2005;42(5):1208-36.

Friedman LS. The risk of surgery in patients with liver disease. Hepatol. 1999;29(6):1617-23.

Ghadir MR, Riahin AA, Havaspour A, Nooranipour M, Habibinejad AA. The relationship between lipid profile and severity of liver damage in cirrhotic patients. Hepatitis monthly. 2010;10(4):285.

Subhan F, Khan I, Arif R, Khan A, Khan A. Serum lipid profile as an indicator of the severity of liver damage in cirrhotic patients. Rawal Med J. 2012;37(4):387-9.

Sanjay Kumar Mandal, Koelina Sil, Sumanta Chatterjee, Jacky Ganguly, Koushik Chatterjee, Pankaj Sarkar, Satanik Hazra, Debasis Sardar. A study on lipid profiles in chronic liver diseases. National J Med Res. 2013;3(1):70-2.